Back to Our Work
Preparing health systems for a once-monthly oral PrEP option
Preparing health systems for a once-monthly oral PrEP option
Preparing health systems for a once-monthly oral PrEP option
Root to Rise is helping countries anticipate and address the policy, delivery, market, and health system conditions needed for future MK-8527 introduction.
Root to Rise is helping countries anticipate and address the policy, delivery, market, and health system conditions needed for future MK-8527 introduction.
Root to Rise is helping countries anticipate and address the policy, delivery, market, and health system conditions needed for future MK-8527 introduction.
Root to Rise is supporting countries to prepare for the future introduction of MK-8527, an investigational once-monthly oral pill for HIV prevention now advancing through phase 3 trials. As a next-generation option with the potential to expand PrEP choice beyond daily pills and injectables, MK-8527 will require markets and health systems that are ready to absorb it. Drawing on lessons from lenacapavir and earlier PrEP rollouts, we are developing country introduction roadmaps that help governments and partners anticipate access barriers, prioritize readiness investments, and turn emerging evidence into practical steps for future MK-8527 introduction.
Root to Rise is supporting countries to prepare for the future introduction of MK-8527, an investigational once-monthly oral pill for HIV prevention now advancing through phase 3 trials. As a next-generation option with the potential to expand PrEP choice beyond daily pills and injectables, MK-8527 will require markets and health systems that are ready to absorb it. Drawing on lessons from lenacapavir and earlier PrEP rollouts, we are developing country introduction roadmaps that help governments and partners anticipate access barriers, prioritize readiness investments, and turn emerging evidence into practical steps for future MK-8527 introduction.
Root to Rise is supporting countries to prepare for the future introduction of MK-8527, an investigational once-monthly oral pill for HIV prevention now advancing through phase 3 trials. As a next-generation option with the potential to expand PrEP choice beyond daily pills and injectables, MK-8527 will require markets and health systems that are ready to absorb it. Drawing on lessons from lenacapavir and earlier PrEP rollouts, we are developing country introduction roadmaps that help governments and partners anticipate access barriers, prioritize readiness investments, and turn emerging evidence into practical steps for future MK-8527 introduction.
At a Glance
At a Glance
Focus Areas
Focus Areas
Product introduction, strategic market preparation
Countries
Countries
Global
Partners
Partners
Gates Foundation
Funder
Funder
Gates Foundation